Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma

被引:28
作者
Uemura, M
Nouso, K
Kobayashi, Y
Tanaka, H
Nakamura, S
Higashi, T
Ono, T
Nakayama, E
Hanafusa, T
Shiratori, Y
机构
[1] Okayama Univ, Grad Sch Med & Dent, Dept Med & Med Sci, Okayama 7008558, Japan
[2] Okayama Citizens Hosp, Dept Med, Okayama, Japan
[3] Okayama Univ, Grad Sch Med & Dent, Dept Immunol, Okayama, Japan
[4] Okayama Univ, Grad Sch Med & Dent, Isotope Ctr, Okayama, Japan
关键词
hepatocellular carcinoma; tumor-associated antigens; tumor markers; Tat binding protein-1; beta 4 integrin-binding protein; ribosomal protein L30;
D O I
10.1002/cncr.11374
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. To identify antigens specifically recognized by the immune surveillance system in patients with hepatocellular carcinoma (HCC), the authors examined two complementary DNA (cDNA) libraries of moderately differentiated HCC by serologic analysis of recombinant cDNA expression libraries (SEREX). METHODS. The libraries were screened with autologous patients' sera, and sequences of the reacted clones were determined. To study the immunoreactivity of the antigens, sera from 20 patients with HCC, from 20 healthy volunteers, and from 16 patients with chronic viral hepatitis were examined. RESULTS. Twenty-seven antigens were identified. They included SART1, p57Kip2, ROCK-1, gamma-catenin, and heat shock proteins, which are classified as tumor-associated genes. Three of 27 antigens-Tat-binding protein-1 (TBP-1), beta4 integrin-binding protein (p27[BBP]), and ribosomal protein L30 (rpL30)-were reacted predominantly with sera from patients with HCC (55% of patients, 45% of patients, and 20% of patients, respectively). Patients in the control group had no antibodies against these three antigens. Seventy percent of patients with HCC had the antibody against at least one of these antigens. CONCLUSIONS. Disease specific humoral immune response against TBP-1, p27(BBP), and rpL30 was induced in patients with HCC, and the antibodies against these antigens also may be used as tumor markers. (C) 2003 American Cancer Society.
引用
收藏
页码:2474 / 2479
页数:6
相关论文
共 36 条
[1]   HBV X protein targets HIV tat-binding protein 1 [J].
Barak, O ;
Aronheim, A ;
Shaul, Y .
VIROLOGY, 2001, 283 (01) :110-120
[2]   Isolation of a novel beta(4) integrin-binding protein (p27(BBP)) expressed in epithelial cells [J].
Biffo, S ;
Sanvito, F ;
Costa, S ;
Preve, L ;
Pignatelli, R ;
Spinardi, L ;
Marchisio, PC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (48) :30314-30321
[3]   A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening [J].
Chen, YT ;
Scanlan, MJ ;
Sahin, U ;
Tureci, O ;
Gure, AO ;
Tsang, SL ;
Williamson, B ;
Stockert, E ;
Pfreundschuh, M ;
Old, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :1914-1918
[4]   Identification, purification, and characterization of a PA700-dependent activator of the proteasome [J].
DeMartino, GN ;
Proske, RJ ;
Moomaw, CR ;
Strong, AA ;
Song, XL ;
Hisamatsu, H ;
Tanaka, K ;
Slaughter, CA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) :3112-3118
[5]   Cell motility mediated by Rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma [J].
Genda, T ;
Sakamoto, M ;
Ichida, T ;
Asakura, H ;
Kojiro, M ;
Narumiya, S ;
Hirohashi, S .
HEPATOLOGY, 1999, 30 (04) :1027-1036
[6]   IMMUNOCHEMOTHERAPY IN HUMAN HEPATOCELLULAR-CARCINOMA USING THE STREPTOCOCCAL AGENT OK-432 [J].
IMAOKA, S ;
SASAKI, Y ;
ISHIKAWA, O ;
OUHIGASHI, H ;
KOYAMA, H ;
IWANAGA, T ;
ISHIGURO, S .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (11) :1645-1651
[7]   Immunoblotting detection of γ-catenin (plakoglobin) antibody in the serum of a patient with paraneoplastic pemphigus [J].
Ishii, M ;
Izumi, J ;
Fujiwara, H ;
Ito, M ;
Hamada, M .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (02) :377-379
[8]   Induction of primary NY-ESO-1 immunity:: CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers [J].
Jäger, E ;
Gnjatic, S ;
Nagata, Y ;
Stockert, E ;
Jäger, D ;
Karbach, J ;
Neumann, A ;
Rieckenberg, J ;
Chen, YT ;
Ritter, G ;
Hoffman, E ;
Arand, M ;
Old, LJ ;
Knuth, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12198-12203
[9]   Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes [J].
Jäger, E ;
Chen, YT ;
Drijfhout, JW ;
Karbach, J ;
Ringhoffer, M ;
Jäger, D ;
Arand, M ;
Wada, H ;
Noguchi, Y ;
Stockert, E ;
Old, LJ ;
Knuth, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (02) :265-270
[10]   Expression of MAGE-1 and-3 genes and gene products in human hepatocellular carcinoma [J].
Kariyama, K ;
Higashi, T ;
Kobayashi, Y ;
Nouso, K ;
Nakatsukasa, H ;
Yamano, T ;
Ishizaki, M ;
Kaneyoshi, T ;
Toshikuni, N ;
Ohnishi, T ;
Fujiwara, K ;
Nakayama, E ;
Terracciano, L ;
Spagnoli, GC ;
Tsuji, T .
BRITISH JOURNAL OF CANCER, 1999, 81 (06) :1080-1087